0001140361-11-034370.txt : 20110628
0001140361-11-034370.hdr.sgml : 20110628
20110628103732
ACCESSION NUMBER: 0001140361-11-034370
CONFORMED SUBMISSION TYPE: D/A
PUBLIC DOCUMENT COUNT: 1
ITEM INFORMATION: Rule 506
FILED AS OF DATE: 20110628
DATE AS OF CHANGE: 20110628
EFFECTIVENESS DATE: 20110628
FILER:
COMPANY DATA:
COMPANY CONFORMED NAME: CoLucid Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001348649
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: D/A
SEC ACT: 1933 Act
SEC FILE NUMBER: 021-156147
FILM NUMBER: 11934680
BUSINESS ADDRESS:
STREET 1: 2530 MERIDIAN PARKWAY
STREET 2: SUITE 300
CITY: DURHAM
STATE: NC
ZIP: 27713
BUSINESS PHONE: 919-806-4304
MAIL ADDRESS:
STREET 1: 2530 MERIDIAN PARKWAY
STREET 2: SUITE 300
CITY: DURHAM
STATE: NC
ZIP: 27713
FORMER COMPANY:
FORMER CONFORMED NAME: Colucid Pharmaceuticals Inc
DATE OF NAME CHANGE: 20060104
D/A
1
primary_doc.xml
X0704
D/A
LIVE
0001348649
CoLucid Pharmaceuticals, Inc.
2530 MERIDIAN PARKWAY
SUITE 300
DURHAM
NC
NORTH CAROLINA
27713
919-806-4304
DELAWARE
Colucid Pharmaceuticals Inc.
Colucid Pharmaceuticals Inc
Corporation
true
Arthur
M.
Pappas
Pappas Ventures, 2520 Meridian Parkway
Suite 400
Durham
NC
NORTH CAROLINA
27713
Executive Officer
Director
Thomas
P.
Mathers
2530 Meridian Parkway
Suite 300
Durham
NC
NORTH CAROLINA
27713
Executive Officer
Director
Jesse
I.
Treu
One Palmer Square
Suite 515
Princeton
NJ
NEW JERSEY
08542
Director
Richard
J.
Markham
47 Hulfish Street
Suite 310
Princeton
NJ
NEW JERSEY
08542
Director
Timothy
C.
Gupton
1500 Sunday Drive
Suite 300
Raleigh
NC
NORTH CAROLINA
27607
Executive Officer
Nadia
M.
Rupniak
2530 Meridian Parkway
Suite 300
Durham
NC
NORTH CAROLINA
27713
Executive Officer
Pharmaceuticals
$1 - $1,000,000
- 06
true
0001140361-11-013783
2011-02-25
false
true
true
false
0
9500000
3500000
6000000
$2,000,000 was sold on February 25, 2011. A Form D was filed at that time. $1,500,000 was sold on June 15, 2011.
false
7
0
0
0
No proceeds are proposed to be used for payment to such persons other than ordinary salary expenses that may be paid out of working capital.
false
CoLucid Pharmaceuticals, Inc.
Timothy C. Gupton
Timothy C. Gupton
Chief Financial Officer
2011-06-27